Abstract A012: Discovery and characterization of Casdatifan (AB521), a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor

癌症研究 缺氧诱导因子 小分子 药理学 血管生成 缺氧(环境) 药效团 药物发现 生物 化学 生物化学 基因 有机化学 氧气
作者
Kenneth V. Lawson,Artur K. Mailyan,Guillaume Mata,Joel W. Beatty,Samuel L. Drew,Jeremy T. A. Fournier,Jarosław Kalisiak,Ahn T. Tran,Kai Ding Wing Yiu Yu,Brandon R. Rosen,Clayton Hardman,Matthew Epplin,Kelsey E. Sivick,Dana Piovesan,Suan Liu,Elaine Ginn,Cesar Meleza,Lisa C. Seitz,Tzuling Cheng,Amber T. Pham
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:23 (12_Supplement): A012-A012 被引量:3
标识
DOI:10.1158/1538-8514.cancerchem24-a012
摘要

Abstract Introduction. The microenvironment of solid tumors is known to be hypoxic and requires induction of genes associated with metabolism, growth, proliferation, angiogenesis, and erythropoiesis for tumor cells to survive and metastasize. Hypoxia-inducible factors (HIFs) are the central driving force for the cellular response to hypoxia and regulate a vast array of these genes. HIF-2α protein levels are tightly regulated post-translationally in an oxygen-dependent manner. Hypoxic conditions or aberrations in the Von-Hippel Lindau (VHL) ubiquitin ligase complex lead to HIF-2α stabilization and transcription of various pro-tumorigenic gene sets. The inhibition of HIF-2α has been demonstrated to be an effective strategy to mitigate tumor growth in the clinic with the recent approval of belzutifan for the treatment of advanced metastatic clear cell renal cell carcinoma (ccRCC). However, belzutifan suffers from saturated drug exposure and peripheral PD effects at its approved dose regimen, casting uncertainty whether optimal intra-tumoral inhibition of HIF-2α was achieved in these studies. Herein, we present the discovery and characterization of casdatifan, a potent and selective small molecule HIF-2α inhibitor, with pharmacokinetic properties optimized to enable deeper PD effects and robust intra-tumoral HIF-2α inhibition. Methods. Applying a pharmacophore mapping and structure-based design approach, we identified multiple novel series of small molecule HIF-2α inhibitors. Interrogation of structure activity relationships and pharmacokinetic trends culminated in the discovery of casdatifan. The potency of casdatifan was evaluated using a suite of biochemical and cell-based assays. Efficacy and pharmacodynamic markers were also evaluated in mice bearing established A498 and 786-O ccRCC xenograft tumors treated with casdatifan. Results. Casdatifan was found to avidly bind the HIF-2α PAS-B domain and potently block HIF-2α-mediated gene transcription under physiologically relevant conditions. Additionally, robust antitumor activity was observed in mouse ccRCC xenograft models following oral administration of casdatifan. Casdatifan exhibits a favorable preclinical pharmacokinetic (PK) profile. In healthy volunteers (ARC-14, NCT05117554), casdatifan showed a favorable PK profile featuring a terminal half-life of 18-24 hours. No evidence of saturable drug absorption has been observed, with dose-proportional increase in exposure across the evaluated dose range. Potent HIF-2α inhibition is demonstrated by dose-dependent reductions in serum EPO, an established peripheral PD marker for HIF-2α inhibition. Conclusions. Extensive optimization of a novel series of HIF-2α inhibitors culminated in the discovery of casdatifan. The PK/PD profile for casdatifan is consistent with a potential best-in-class HIF-2α inhibitor, with deeper reductions of peripheral biomarkers than has been reported by clinical competition. Continued evaluation of casdatifan in patients with ccRCC and other advanced solid tumors is underway (ARC-20, NCT05536141). Citation Format: Kenneth V. Lawson, Artur Mailyan, Guillaume Mata, Joel W. Beatty, Samuel L. Drew, Jeremy T. A. Fournier, Jaroslaw Kalisiak, Ahn T. Tran, Kai Yu, Brandon R. Rosen, Clayton Hardman, Matthew Epplin, Kelsey E. Sivick, Dana Piovesan, Suan Liu, Elain Ginn, Cesar A. Meleza, Lisa Seitz, Tzuling Cheng, Amber Pham, Mohammad Ghasemi, Paul G. Foster, Matthew J. Walters, Manmohan Leleti, Jay P. Powers. Discovery and characterization of Casdatifan (AB521), a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry; 2024 Dec 9-11; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(12_Suppl):Abstract nr A012.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
Jolene完成签到,获得积分10
1秒前
2秒前
流年发布了新的文献求助10
2秒前
2秒前
隐形曼青的应助被周小鱼采纳,获得10
2秒前
李爱国的应助被有人喜欢蓝采纳,获得10
2秒前
OK完成签到 ,获得积分10
2秒前
存亿点好运完成签到,获得积分10
3秒前
3秒前
3秒前
3秒前
小冯同学完成签到,获得积分10
3秒前
英俊的铭的应助被从容的凡双采纳,获得10
4秒前
4秒前
仇道罡完成签到,获得积分10
4秒前
Lotus发布了新的文献求助10
4秒前
天天快乐的应助被yumi采纳,获得10
4秒前
5秒前
5秒前
seet完成签到,获得积分10
6秒前
爆米花的应助被蔡慧学采纳,获得10
6秒前
赤道的雪发布了新的文献求助10
6秒前
跳跃的紫文完成签到 ,获得积分10
6秒前
6秒前
阳光奎发布了新的文献求助30
6秒前
tiptip的应助被211107采纳,获得30
7秒前
科研通AI6.4的应助被211107采纳,获得10
7秒前
Cheryl完成签到,获得积分10
7秒前
终梦的应助被211107采纳,获得10
7秒前
科研通AI6.4的应助被211107采纳,获得10
7秒前
科研通AI6.4的应助被211107采纳,获得10
7秒前
搞怪的老九的应助被211107采纳,获得10
8秒前
8秒前
邦尼老师发布了新的文献求助10
8秒前
新楚发布了新的文献求助10
8秒前
OK关注了科研通微信公众号
8秒前
8秒前
杜仲_商陆完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417